![](https://www.pymnts.com/wp-content/uploads/2020/03/shutterstock_1636729108-e1632311969168-4.jpg)
Britain’s competition regulator has been told to review its evidence against US drugmaker Pfizer and Flynn Pharma in the UK as it seeks to reinstate a record £90m fine for excessive drug pricing, reported The Financial Times.
The drugmakers have avoided paying the fine after winning an appeal against the Competition and Markets Authority’s decision in 2018. The CMA took the case to the Court of Appeal, which on Tuesday dismissed three of its four grounds of objection to the tribunal’s decision.
In its judgment the court said the CMA should reconsider evidence that the companies had abused their dominant position to increase prices as well as the scale of any fine. But the court agreed that it did not have to set a theoretical benchmark when assessing abuse in relation to pricing drugs.
The ruling comes after the CMA fined Flynn and Pfizer £90m four years ago for abusing their dominant market position by increasing the price of an anti-seizure drug, relied upon by 48,000 epilepsy patients in the UK, by 2,285 per cent overnight in 2012.
Featured News
Canadian Breadmakers Settle Price-Fixing Lawsuit
Jul 25, 2024 by
CPI
EssilorLuxottica Open to Meta as Shareholder, Says CEO Francesco Milleri
Jul 25, 2024 by
CPI
California Supreme Court Upholds Proposition 22, Securing Independent Contractor Status for Uber and Lyft Drivers
Jul 25, 2024 by
CPI
Paramount Global Investor Sues to Block Skydance Media Merger
Jul 25, 2024 by
CPI
Software Vendors Win Class Action Status in Antitrust Case Against CDK Global
Jul 25, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Trade & Antitrust
Jul 26, 2024 by
CPI
What is Wrong with the WTO Discipline on Subsidies?
Jul 26, 2024 by
CPI
The Abiding Tension Between Trade Remedy Law and Antitrust
Jul 26, 2024 by
CPI
Trade and Antitrust: An End to Isolationism
Jul 26, 2024 by
CPI
International Trade Law and Domestic Regulation of Generative Artificial Intelligence: Divergent Approaches?
Jul 26, 2024 by
CPI